A new experimental pill may soon offer hope to millions of people living with obstructive sleep apnea, a condition that disrupts breathing during sleep and leaves many patients exhausted every day.
Researchers say the medicine, called AD109, could become the first pill designed to directly treat the biological causes of sleep apnea rather than relying on machines or surgery.
The results of the major clinical trial were presented at the 2026 ATS International Conference and published in the American Journal of Respiratory and Critical Care Medicine.
Obstructive sleep apnea, often called OSA, happens when the airway repeatedly closes or becomes blocked during sleep. This causes people to stop breathing for short periods many times during the night.
Some patients stop breathing dozens or even hundreds of times while sleeping. Each interruption lowers oxygen levels and forces the brain to partially wake the body so breathing can restart.
Over time, this repeated stress can lead to serious health problems. Untreated sleep apnea has been linked to high blood pressure, heart attacks, strokes, diabetes, depression, poor concentration, memory problems, and increased accident risk due to daytime sleepiness. Many people with the condition also struggle with loud snoring and poor-quality sleep.
The standard treatment for OSA has long been CPAP therapy. CPAP machines use air pressure delivered through a face mask to stop the airway from collapsing.
Although the treatment works well for many people, a large number of patients stop using it because they find it uncomfortable or difficult to tolerate. Some patients dislike sleeping with a mask, while others feel claustrophobic or struggle with dry mouth and sleep disruption.
Because of this, scientists have been searching for easier treatment options for years. AD109 may finally provide one.
The large Phase III trial, known as SynAIRgy, included 646 adults with mild to severe sleep apnea across 69 medical sites in the United States and Canada. All of the participants had either refused CPAP treatment or could not continue using it.
The drug combines two existing medicines called aroxybutynin and atomoxetine. Together, these drugs help strengthen and activate the muscles that keep the throat open during sleep. In many people with sleep apnea, these muscles relax too much during the night, causing the airway to narrow or collapse.
Researchers found that patients taking AD109 experienced major improvements in breathing during sleep. Their apnea-hypopnea index, which measures the number of breathing interruptions each hour, fell by around 44%. In the placebo group, the improvement was only about 18%.
Patients taking the drug also showed healthier oxygen levels throughout the night. This is important because low oxygen levels place strain on the heart and brain and may contribute to long-term disease.
One of the most encouraging findings was that more than 40% of patients improved enough to move into a less severe category of sleep apnea. Around 18% achieved what researchers described as complete disease control.
Dr. Patrick John Strollo, the lead researcher and a sleep medicine expert at the University of Pittsburgh Medical Center, said the study supports a growing understanding that sleep apnea is not simply caused by weight or anatomy alone. Problems involving nerve and muscle control in the airway also play a major role in many patients.
The researchers found that the drug worked across a wide range of participants, including people with different body sizes and different levels of disease severity. This suggests the treatment may help many different types of patients rather than only a small subgroup.
Safety was also closely monitored during the study. The most common side effects included dry mouth, nausea, insomnia, and difficulty urinating. Most side effects were mild and expected based on how the medicines work. However, about 21% of participants stopped taking the drug because of side effects.
Experts say the results are still highly important because untreated sleep apnea remains a massive public health problem. Millions of people either remain undiagnosed or do not continue treatment after trying CPAP.
Researchers believe an easy-to-take pill could dramatically increase the number of people receiving treatment. Unlike CPAP machines, a nightly pill may feel simpler and less disruptive to daily life.
The company developing the medicine, Apnimed, has already submitted a New Drug Application to the U.S. Food and Drug Administration. The FDA has also granted the medicine Fast Track designation, which is used for treatments that could address serious unmet medical needs.
Scientists involved in the study also published additional research explaining the biological mechanisms behind the drug’s effects. These companion studies strengthen confidence that targeting throat muscle control may become an entirely new way to treat sleep apnea.
The findings could represent a turning point in sleep medicine. For decades, patients have had limited options outside CPAP devices, mouth guards, surgery, and lifestyle changes. A successful oral medication would be a major breakthrough.
Still, experts caution that more research will be needed. The trial lasted six months, so scientists still need to study the long-term effects and safety of the treatment over many years. Researchers also need to understand which patients are most likely to benefit and whether the drug can reduce long-term risks such as heart disease and stroke.
Even with these unanswered questions, the study offers real hope for people who struggle nightly with sleep apnea and cannot tolerate existing treatments. If approved, AD109 may become one of the first medicines to directly target the biological causes of airway collapse during sleep, potentially changing the future of sleep apnea care.
If you care about sleep health, please read studies about foods that help people sleep better, and Keto diet could improve cognitive function in people with sleep loss.
For more health information, please see recent studies about the natural supplements for sound sleep, and how your diet can improve sleep quality.
